The Molbio Diagnostics IPO legal advisors — Khaitan & Co, Cyril Amarchand Mangaldas, and Hogan Lovells Cadwalader — have completed their mandates on one of the more closely watched healthcare listings of the year. Molbio Diagnostics has raised ₹939.696 crore from an initial public offering of equity shares, comprised of a fresh issue and an offer for sale. The issue was subscribed 70.26 times, with bidding opening on 10 August 2026 and closing on 12 August 2026.
Introduction
Molbio Diagnostics is a point-of-care diagnostics company that develops and manufactures healthcare technologies for diagnosing infectious and non-communicable diseases, with its core business revolving around the proprietary ‘Truenat’ platform — a portable, battery-operated PCR system designed for use in resource-limited settings. The IPO is structured as a combination of a fresh issue of equity shares and an offer for sale. The fresh issue component is worth up to ₹200.16 crore, while the offer for sale component amounts to up to ₹739.70 crore.
The book-running lead managers on the issue were Kotak Mahindra Capital Co. Ltd., IIFL Capital Services Ltd., Jefferies India Pvt. Ltd., and Motilal Oswal Investment Advisors Ltd. The shares were listed on NSE and BSE on 17 August 2026.
Deal Value
Molbio Diagnostics raised ₹939.696 crore from the IPO, comprising a fresh issue and an offer for sale of equity shares. The price band was fixed between ₹768 and ₹807 per share. The company plans to spend up to ₹105.54 crore from the fresh issue proceeds for building a new research and development facility and Centre of Excellence, against a total estimated cost of ₹125.12 crore. The remaining fresh issue proceeds will be directed towards plant, machinery and equipment for manufacturing units, and general corporate purposes.
Legal Teams Involved
Three firms advised on this transaction, covering the issuer, the book-running lead managers, and international counsel mandates respectively.
Advising Molbio Diagnostics (Issuer): Khaitan & Co
Khaitan & Co advised Molbio Diagnostics on this IPO. The transaction team consisted of the following members:
- Abhimanyu Bhattacharya (Partner)
- Gautham Srinivas (Partner)
- Sathvik Ponnappa (Partner)
- Sanjeev Chowdhary (Principal Associate)
- Vaishnavi Gupta (Senior Associate)
- Mainak Pani (Associate)
- Shambhavi Gautam (Associate)
Advising the Book-Running Lead Managers: Cyril Amarchand Mangaldas
Cyril Amarchand Mangaldas advised the book-running lead managers — Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited, and Motilal Oswal Investment Advisors Limited — on this IPO. The transaction was led by the following team:
- Yash J. Ashar (Senior Partner)
- Priyadarshini Rao (Partner)
- Raksha Raina (Senior Associate)
- Prakhar Jain (Associate)
- Janhavi Deshmukh (Associate)
- Zubin Ronnie (Associate)
- Aria Sheth (Associate)
- Namita Kaushik (Associate)
International Counsel to the Lead Managers: Hogan Lovells Cadwalader
Hogan Lovells Cadwalader acted as International Counsel for the lead managers. The transaction team was led by:
- Biswajit Chatterjee (Head of the India Practice and Dubai Office Managing Partner)
Significance and Impact
The Molbio Diagnostics IPO is notable for both its robust investor demand and the strategic deployment of its proceeds. The qualified institutional buyers’ portion was subscribed 186.39 times, while the non-institutional investors’ category was subscribed 49.80 times. The retail individual investors’ segment was subscribed 12.96 times.
The company’s flagship Truenat platform is a portable, battery-operated PCR system designed for use in resource-limited settings, providing rapid and accurate test results within approximately one hour. The platform’s ability to enable decentralised, battery-operated diagnosis positions Molbio at the intersection of diagnostics technology and public healthcare access — a segment attracting increasing investor attention in India and globally.
At listing, the stock opened at ₹980 on the Bombay Stock Exchange, at a premium of 21.44%. The three-firm legal structure — domestic issuer counsel, domestic banker counsel, and international counsel — reflects the cross-border complexity increasingly standard in Indian healthcare IPOs of this scale. Track more mandates of this nature on the Deal Meter.
The Molbio Diagnostics IPO represents a significant capital markets milestone for the Indian point-of-care diagnostics sector. Khaitan & Co, Cyril Amarchand Mangaldas, and Hogan Lovells Cadwalader collectively discharged issuer, banker, and international counsel mandates on the ₹939.696 crore offering. The strong subscription response and a 21%-plus listing premium underscore robust institutional and retail confidence in the company’s Truenat-led growth thesis.
Disclaimer: This article is for informational purposes only and does not constitute legal advice. It is based on the details provided and publicly available sources.
